Fig. 1 · Structure

Documents & Downloads

Bimatoprost

Cat. No. A10145 CAS 155206-00-1
Bimatoprost is a prostaglandin analog/prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Bimatoprost produced acute impedance increases in primary human ocular outflow cells, and an orthogonal actin assay showed a reduced F-actin/G-actin ratio in trabecular meshwork cells. These findings support altered cell behavior compatible with relaxation; impedance also reflects cell contacts and does not identify a unique molecular receptor. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Bimatoprost Research Summary

This section summarizes 3 in vitro studies and 3 in vivo studies of Bimatoprost from 3 published references.

Bimatoprost In Vitro Studies

In primary human trabecular meshwork, Schlemm’s canal, and ciliary smooth muscle cultures, bimatoprost increased monolayer impedance with reported functional EC50 values of 4.3, 1.2, and 1.7 nM, respectively. These are assay-specific response potencies, rather than treatment concentrations or binding affinities. [1]

In perfused human donor anterior segments, 1 μM bimatoprost increased conventional outflow facility by 40% from baseline after 48 hours (10 segments). Antagonist co-treatment and pretreatment groups showed smaller descriptive responses. The experiment used active contralateral comparators and baseline controls; corneal thickness also increased during exposure and returned toward baseline after washout. [2]

Acute impedance responses in primary human ocular outflow cells

Cell-based study · Primary human trabecular meshwork (TM), Schlemm’s canal (SC), and ciliary smooth muscle (CSM) monolayers. [1]

Bimatoprost increased impedance in all three cell types. Buffer-only signals were subtracted; fluprostenol and 17-phenyl PGF2α served as FP-agonist comparisons. Cicaprost and U46619 established differential impedance responses in separate control exposures. Increased impedance is compatible with relaxation, but also reflects cell-contact changes, especially in SC.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Functional EC50 for increased monolayer impedanceEC50 TM: 4.3 nM; SC: 1.2 nM; CSM: 1.7 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Agonist concentration-response series; CDS methods state 1 pM–1 μM, while Figure 2 extends to 10 μM and normalization used 10 μM bimatoprost.
Exposure duration
10 minutes of real-time recording after ligand addition
Method
Cellular dielectric spectroscopy (CellKey); baseline 2 minutes at 37°C
Vehicle
Hanks HEPES buffer with 0.1% BSA; buffer-only wells were controls.
Reported limits
Exact point-by-point dosing list and stock solvent are not specified in the adopted assay description.
Methods and source locations

Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost

Results apply to the tested material and model; they do not establish performance of an Adooq lot.

Materials and Methods: Cell Culture, Chemicals, Cellular Dielectric Spectroscopy, Statistical Analysis; Results, Figures 1–2

Functional EC50 for increased monolayer impedance: Buffer-subtracted MAX−MIN impedance response; normalized to maximum bimatoprost response at 10 μM. Curves: mean ± SEM, three independent experiments using two strains per cell type as stated in caption. — Results paragraph preceding Figure 2; Figure 2 and caption; CDS and Statistical Analysis

Actin polymerization assay in human trabecular meshwork cells

Cell-based study · Mature primary human TM monolayers; two strains, n = 4 as reported. [1]

Bimatoprost decreased the F-actin/G-actin ratio, providing an orthogonal cellular readout consistent with the impedance-based relaxation interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
F-actin/G-actin ratioratio 0.61 ± 0.20 with bimatoprost vs 0.79 ± 0.26 control (mean ± SD); n = 4; P = 0.03[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
30 minutes
Method
Actin fractionation followed by immunoblot densitometry after 2-hour serum starvation
Reported limits
Methods describe untreated controls, while Results call them vehicle-treated; vehicle identity is not specified. The n = 4 unit is not further defined.
Methods and source locations

Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost

Results apply to the tested material and model; they do not establish performance of an Adooq lot.

Materials and Methods: Filamentous/Globular Actin Assay; Results paragraph beginning “We validated CDS findings”

F-actin/G-actin ratio: Fractionated actin quantified by immunoblot densitometry; phalloidin-treated untreated lysate served as a positive fractionation control. Assay methods describe a two-tailed paired Student’s t-test “assuming unequal variance”; preserve this unusual wording without reconstructing analysis. — Results: actin validation paragraph; Filamentous/Globular Actin Assay

Conventional outflow facility in perfused human donor anterior segments

Cell-based study · Ex vivo human anterior segments: 20 segments from 11 donors, 49–91 years; 10 bimatoprost-only segments, 4 contralateral co-treatment segments, 6 antagonist-pretreated segments. [2]

Bimatoprost increased facility from each segment’s stable baseline. Antagonist co-treatment and pretreatment produced smaller descriptive changes. These controls were pharmacologically active, rather than a parallel untreated time control. Corneal thickness also increased during bimatoprost exposure and returned toward baseline after washout.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Change in conventional outflow facility from stable baseline in bimatoprost-only segmentspercent change 14% at 24 hours (P = 0.001); 40% at 48 hours (P = 0.0002); 49% at 72 hours after initial exposure, following washout (P = 0.001); n = 10 segments[2]
Facility changes in antagonist comparison segmentspercent change Concurrent AGN211334 + bimatoprost (n = 4): +6% at 24 hours (P = 0.02), +23% at 48 hours (P = 0.03), +17% after washout (P = 0.3). Pretreatment group (n = 6): −4% with AGN211334 alone (P = 0.04), +2% after bimatoprost addition (P = 0.3), −1% after washout (P = 0.5).[2]
Central corneal thickness during bimatoprost-only exposurethickness 778 ± 37 μm immediately before treatment; 832 ± 37.1 μm after 2 days (P = 0.015); 784 ± 56.8 μm 2 days after washout (P = 0.4)[2]

Literature-Reported Treatment Conditions

Treatment concentration
Bimatoprost 1 μM; AGN211334 30 μM in comparison segments
Exposure duration
48-hour bimatoprost exposure; antagonist pretreatment 24 hours where applicable; fresh-medium washout afterward
Method
Constant-flow anterior segment organ perfusion at 2.5 μL/min; baseline stable for at least 24 hours before treatment
Vehicle
Ethanol stocks diluted into DMEM-based perfusion medium; final ethanol content not reported.
Co-treatment
Bimatoprost alone compared with concurrent AGN211334 plus bimatoprost, or AGN211334 pretreatment followed by both drugs.
Reported limits
No parallel vehicle-only segment arm in the adopted comparison. Donor-pair design and different antagonist schedules should not be treated as independent randomized drug-versus-vehicle arms.
Methods and source locations

Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost

Results apply to the tested material and model; they do not establish performance of an Adooq lot.

Methods: Materials, Anterior Segment Perfusion Model, Central Corneal Thickness, Morphological Analysis, Statistical Analysis; Results: Bimatoprost and AGN211334 Effects on Outflow Facility and Bimatoprost and Central Corneal Thickness; Tables 2–3; Figures 2–3, 5

Change in conventional outflow facility from stable baseline in bimatoprost-only segments: (Cd−Co)/Co × 100%; reported group summaries mean ± SEM. Paired t-test; Methods threshold P < 0.01. Baseline facility 0.18 ± 0.04 μL/min/mmHg. — Results: facility summary; Table 3; Figure 3

Facility changes in antagonist comparison segments: Changes relative to original baseline. The source calls some P = 0.02–0.04 changes significant despite its P < 0.01 Methods threshold; no significance claim is adopted for those changes. — Results: facility summary; Table 3; Figures 2–3

Central corneal thickness during bimatoprost-only exposure: Pachymetry; source mean ± SEM. Report descriptive increase; P = 0.015 does not meet the stated P < 0.01 threshold. — Results: Bimatoprost and Central Corneal Thickness; Figure 5

Bimatoprost In Vivo Studies

In normotensive cynomolgus monkeys, topical 0.01% bimatoprost given twice daily for nine doses increased directly measured uveoscleral outflow, while total outflow facility did not change significantly. A separate three-dose 0.1% regimen did not meaningfully suppress aqueous humor flow. These results describe different experimental regimens and should not be generalized to human conventional outflow. [3]

Direct uveoscleral outflow in normotensive monkeys

Animal study · Normotensive cynomolgus monkeys, both sexes, 2.2–4.0 kg; n = 6. [3]

Bimatoprost increased directly measured uveoscleral outflow relative to contralateral vehicle under this experimental regimen.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Direct uveoscleral outflowflow 1.37 ± 0.27 μL/min with bimatoprost vs 0.96 ± 0.20 μL/min vehicle; mean ± SEM; n = 6; P < .05; reported increase 42%[3]

Conditions shared by the study groups

Route
Topical ocular administration
Frequency
Twice daily
Treatment course
9 administrations over 4.5 days; assessed on day 5, 5–7 hours after final dose
Vehicle
5 mM TRIS-HCl / 0.1% polysorbate 80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bimatoprost with paired contralateral vehicle
25 μL of 0.01% bimatoprost per administration
Contralateral eye given vehicle identically.Uveoscleral outflow increased from 0.96 ± 0.20 to 1.37 ± 0.27 μL/min (mean ± SEM; n = 6; P < .05).[3]
Bimatoprost with paired contralateral vehicle
Model: Ocular normotensive cynomolgus monkeys of both sexes; n = 6 as reported.
Methods and source locations

Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost

Results apply to the tested material and model; they do not establish performance of an Adooq lot.

Section 2: uveoscleral tracer perfusion and shared dosing; section 3.1; Table 2

Direct uveoscleral outflow: Anterior chamber perfusion with FITC-dextran tracer and tissue recovery; paired Student’s t-test. — Section 3.1 and Table 2; Section 2

Bimatoprost with paired contralateral vehicle · Section 2: uveoscleral tracer perfusion and shared dosing; section 3.1; Table 2

Total outflow facility before and after bimatoprost in normotensive monkeys

Animal study · Normotensive cynomolgus monkeys, both sexes, 2.2–4.0 kg; n = 6. [3]

No significant total outflow facility effect was observed after bimatoprost treatment compared with naïve baseline and contralateral vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total outflow facilityoutflow facility Treated-eye baseline 0.42 ± 0.05 and post-treatment 0.42 ± 0.04 μL min−1 mmHg−1; vehicle-eye baseline 0.46 ± 0.03 and post-treatment 0.37 ± 0.02; mean ± SEM, n = 6. No significant drug effect reported.[3]

Conditions shared by the study groups

Route
Topical ocular administration
Frequency
Twice daily
Treatment course
9 administrations over 4.5 days; assessed on day 5, 5–7 hours after final dose
Vehicle
5 mM TRIS-HCl / 0.1% polysorbate 80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bimatoprost with paired contralateral vehicle
25 μL of 0.01% bimatoprost per administration
Contralateral eye given vehicle identically; total facility also compared with naïve baseline approximately 4 months earlierNo significant drug effect on total outflow facility; treated-eye mean 0.42 μL min−1 mmHg−1 at baseline and after treatment.[3]
Bimatoprost with paired contralateral vehicle
Model: Ocular normotensive cynomolgus monkeys of both sexes; n = 6 as reported.
Methods and source locations

Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost

Results apply to the tested material and model; they do not establish performance of an Adooq lot.

Section 2: shared dosing and total outflow facility methods; section 3.1; Table 1

Total outflow facility: Two-level constant-pressure method; naïve baseline and treatment measurements approximately 4 months apart. — Table 1 and Section 3.1; Section 2

Bimatoprost with paired contralateral vehicle · Section 2: total outflow facility methods; section 3.1; Table 1

Aqueous humor flow with bimatoprost and a separate timolol reference series

Animal study · Normotensive cynomolgus monkeys; Table 3 reports n = 6. [3]

Bimatoprost did not meaningfully suppress aqueous flow. Timolol reduced flow in a separate reference experiment; it was not combined with bimatoprost.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Aqueous humor flowflow Bimatoprost: 1.497 ± 0.07 vs paired vehicle 1.41 ± 0.07 μL/min, no meaningful effect. Timolol: 0.91 ± 0.09 vs paired vehicle 1.64 ± 0.14 μL/min, P < .05. Mean ± SEM, n = 6 as Table 3 reports.[3]

Conditions shared by the study groups

Route
Topical ocular administration
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Bimatoprost aqueous-flow series
0.1% bimatoprost; administered volume not reported for this series
Contralateral vehicle eyeNo meaningful suppression of aqueous humor flow[3]
Timolol reference series
0.5% timolol; administered volume not reported
Contralateral vehicle eyeAqueous flow suppressed by about 42%; reference drug was tested in a separate series[3]
Bimatoprost aqueous-flow series
Model: Ocular normotensive cynomolgus monkeys of both sexes; n = 6 as reported.
Frequency: Two administrations 6 hours apart on preceding day, then one on measurement morning
Treatment course: Three administrations total
Vehicle: Vehicle control described; formulation for this separate flow series is not separately specified.
Reported limits: Do not borrow 25 μL volume from the 0.01% outflow protocol.
Timolol reference series
Model: Ocular normotensive cynomolgus monkeys of both sexes; n = 6 as reported.
Frequency: Single administration on measurement day
Treatment course: One administration
Vehicle: Vehicle control described; formulation not specified for this series.
Methods and source locations

Compound reported in the paper: Bimatoprost; Compound label in the paper: Bimatoprost

Results apply to the tested material and model; they do not establish performance of an Adooq lot.

Section 2: aqueous-flow methods and final dosing paragraph; section 3.1; Table 3

Aqueous humor flow: Scanning ocular fluorophotometry; separate bimatoprost and timolol series with paired vehicle eyes. — Table 3 and section 3.1; Section 2

Bimatoprost aqueous-flow series · Section 2 final paragraph; Table 3

Timolol reference series · Section 2 final paragraph; Table 3

Specifications

Manufacturer Adooq Bioscience
CAS Number 155206-00-1
Formula C25H37NO4
Molecular Weight 415.6
Synonyms Lumigan
SMILES
CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 31 mg/mL (74.59 mM)
Water Insoluble
Ethanol 71 mg/mL (170.84 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bimatoprost Research References

  1. [1] Stamer WD, Piwnica D, Jolas T, et al. Cellular basis for bimatoprost effects on human conventional outflow. Investigative ophthalmology & visual science (2010). PMID: 20435598 DOI: 10.1167/iovs.09-4955 Source material
  2. [2] Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Investigative ophthalmology & visual science (2007). PMID: 17724194 DOI: 10.1167/iovs.07-0080 Source material
  3. [3] Woodward DF, Krauss AH, Nilsson SF. Bimatoprost effects on aqueous humor dynamics in monkeys. Journal of ophthalmology (2010). PMID: 20508775 DOI: 10.1155/2010/926192 Source material

Added to your cart

View Cart Checkout
Loading...